Company: PETVW
Filing Date: 2025-06-24
Form Type: 8-K
Source: 0001641172-25-016271
Chunk: 0

Company: PetVivo Holdings, Inc.
Filing Date: 2025-06-24
Form: 8-K
Item: Item 3.02
Chunk 0
---
Item      Unregistered                 

On
June 24, 2025, PetVivo Holdings, Inc., including its wholly-owned subsidiary PetVivo Animal Health, Inc., (collectively the “ Company”,
“we” and “us”) received One Million Dollars ($1,000,000) pursuant to the full exercise of the remaining Shares
offered in a purchase option (“ Purchase Option”) granted to the investor as part of an offering to receive Five Million Dollars
($5,000,000) of equity financing in exchange for Five Million shares of Series B Convertible Preferred Stock (“ Shares”) (the
“ Offering”); pursuant to the Offering, the purchase price for one (1) Share of Series B Convertible Preferred Stock is One
Dollar ($1.00) and the conversion rate is one (1) Share of Series B Convertible Preferred Stock for one (1) share of Company common stock.
The Company has previously received an aggregate total of Four Million Dollars ($4,000,000) of the Offering prior to the current Purchase
Option exercise. The exercise of the remaining One Million Dollars ($1,000,000) of the Purchase Option completes the issuance of all
Shares allowed and thereby closes the Purchase Option of the Offering.

The
Offering was conducted pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended
(“ Securities Act”). The investor entered into the Subscription Agreement with the Company and represented in writing that
he, she, or it is an “accredited investor” (as such term is defined in Rule 501(a) of Regulation D under the Securities Act)
and acquired the securities for his, her or its own account for investment purposes and any subsequent transfer or sales of these securities
will be in accordance with the Securities Act or exempt from registration under the Securities Act. The shares of Series B Preferred
Stock will be “restricted securities” under Rule 144 of the Securities Act, and certificates representing the foregoing will
bear a Rule 144 restrictive legend.

The
form of Subscription Agreement is filed as Exhibit 10.1 to this Current Report on Form 8-K and the description in this Current Report
on Form 8-K of terms of Subscription Agreement are qualified in their entirety by reference to such exhibits.

In
connection with the Offering, on March 26, 2025, the Company filed a Certificate of Designation of Rights and Preferences of Series B
Convertible Preferred Stock (